Management of venous thromboembolism by Rosendaal, F.R.
The New England Journal of Medicine
drome vvho have micrognathia, growth Hormone can Help
the mandible catch up to the maxilla, whereas in girls who
do not have micrognathia, increased mandibular growth
can lead to an underbite, mainly due to vertical growth of
the ramus of the mandible. This is quite different from ac-
romcgaly, of course, in which the entire mandible enlarges
and protrudes.
I agrec with Dr. Taback and colleagues that we really do
not know yet how best to introduce estrogen therapy in
short patients with Turner's syndrome. Estrogen should
probably be introduced only when patients are near their
final height. In a study that combined very low doses of
estrogen (25 ng per kilogram of body weight per day)3
with growth Hormone, there was a slight additive effect on
growth velocity but also an accelcrated increase in bone-
age maturation in girls with bone ages ofless than 11 years
and chronological ages between 13 and 14 years. Hence,
I recommend 14 years äs a rational age for starting estro-
gen supplementation. The low doses Taback et al. recom-
mend have not yet been tested in Turner's syndrome. De-
spite the variable height outcomes after growth Hormone
therapy in patients with Turner's syndrome, a Food and
Drug'Administration (EDA) advisory committee recom-
mcndcd this therapy nearly unanimously at its meeting on
Deccmber 10, 1996. The EDA has since granted market-
ing clearance, äs have authorities in 27 other countries.
Although the issue of adequate bone mincral density is
difficult to assess in Turner's syndrome,4 because of a fre-
quent intrinsic "osteopenic" appearance of the bone, we
should take heart from the report by Ncely et al., which
demonstrates that adolescents with Turner's syndrome
who receive growth Hormone arc not osteopenic and have
normal bone mineral density. The report concludes that
early estrogen replacement cannot be justified on the basis
of bone mineral Status.5
As Gargan and Peerzada point out, wc need a national
data base. The U.S. Turner Syndrome Society (1313 S.E.
5th Street, Minncapolis, MN 55414; fax: [612] 379-3619)
is devcloping one and welcomcs data submissions.
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Management of Venous Thromboembolisni
To the Editor: In his review of the management of
venous thromboembolism (Dec. 12 issue),1 Ginsbcrg
failcd to mention the role of echocardiography in the di-
agnosis of this disorder. Despite the importance of venti-
lation-perfusion lung scanning, it has its limitations. It
usually necessitates the transfer of the patient, who may be
acutely dyspneic, to the radiology department and occa-
sionally to a different hospital. On the other Hand, echo-
cardiography, whether transthoracic or transesophageal, is
widely available, carries a minimal risk or none, and can
help in making the diagnosis at the bedside. In the absence
of chronic pulmonary disease, echocardiographic features
that suggest pulmonary embolism include a dilated hypo-
kinctic right vcntricle and the presence of tricuspid regur-
gitation with increased velocity, suggesting an elevation of
the pulmonary arterial systolic pressure. The absence of
left ventricular dysfunction helps rule out the cardiac dis-
ease äs a cause of acute dyspnea. Visualization of a right
atrial thrombus confirms the diagnosis.2
Bedside echocardiography is a practical diagnostic pro-
cedure that in some patients eliminates the need for fur-
ther studies.
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To the Editor: We think Ginsberg failed to emphasize the
importance of recurrent embolism. All patients with pul-
monary embolism are at risk for further embolism, and
therefore, diagnosing pulmonary embolism is not enough.
Instead, every patient should be evaluated for residual
large thrombi, from the popliteal vein to the vena cava,
by Doppier ultrasonography or venography. Patients with
largc residual thrombi may die from recurrent embolism,
whereas patients without thrombi will not. Whether throm-
bolytic therapy prevents recurrent embolism is unknown.
Vcna caval filters are effective in preventing pulmonary em-
bolism.1 Placement of a vena caval filter may be the pivotal
Step to prevcnt death — by preventing further embolism
in patients with pulmonary embolism who have residual
venous thrombi.
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To the Editor: We agree with Ginsberg that the duration
of anticoagulant therapy in patients who have venous
thromboembolism should be determined by balancing the
risks of continuing therapy against the risk of recurrent
thrombosis and the complications of therapy. He points
out that there are no data to assist us in making decisions
about the use of anticoagulation therapy in asymptomatic
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carriers of a thrombophilic dcfcct (i.e., anticoagulation
treatmenr restricted to high-risk situations vs. life-long
prophylaxis) or in thcse same patients after a first throm-
botic cvent (i.e., treatment for thrce to six months vs. lifc-
long treatment). However, there is evidence that overall
mortality in families with antithrombin deficiency and pro-
tein C deficiency does not differ from that in the general
population.'·2 The mortality rates in diese families were
calculated back into the previous Century, beforc thrombo-
philia was recognized and beforc anticoagulation therapy
cxisted. These results also hold truc for the most scvere
type of thrombophilia, type I antithrombin deficiency.3
Although these results are general and cannot guide
managemcnt in the case of patients with recurrcnt throm-
bosis or families that appear to be extremely prone to
thrombosis, they are reassuring and do not Support the use
of prophylactic anticoagulation solely on'tthc basis of the
presence of the biochemical defect, especially in the light
of the known risks of the therapy (a l to 3 percent risk of
major hemorrhage per year and a 0.3 to 0.6 percent risk
of fatal hemorrhage per year).4'5
On the basis of these retrospectivc data, wc bclieve that
asymptomatic patients with heritable thrombophilia should
not reccive anticoagulant agents except in situations in
which the risk of thrombosis is increased — for examplc,
after surgery and during immobilization.
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Dr. Ginsberg replies:
To the Editor: Ibrahim suggests that echocardiography is
a practical procedure that eliminates the need for further
studies in some patients with suspected pulmonary embo-
lism. In a patient with suspected pulmonary embolism and
a clear-cut right atrial thrombus, a diagnosis of pulmonary
embolism can be made. However, the frequency of this
finding is probably very low, since the source of pulmo-
nary embolism in most patients is leg-vein thrombosis.1
Although in the absence of chronic pulmonary diseasc, a
dilated, hypokinetic right ventricle with or without tricus-
pid insufficiency may be diagnostic of pulmonary embo-
lism, the accuracy of this finding has not been establishcd.
Overall, the clinical Utility of echocardiography in the eval-
uation of patients with suspected pulmonary embolism is
not known. Furthermore, clinicians should not be distract-
ed'from performing tests that have a clear-cut Utility in di-
agnosing pulmonary embolism, such äs lung scanning,
venous ultrasonography, or pulmonary angiography.
Pcchlaner and colleagues suggest that all patients with
established pulmonary embolism should undergo exten-
sive cvaluation to determine the presence (and extent) of
dcep-vein thrombosis, with the placement of a vena caval
filter if large residual thrombi are present. Such an ap-
proach is costly and associated with side effects'(of venog-
raphy, cavography, and insertion of the filter) and in vicw
of the clear-cut efficacy of anticoagulant therapy, cannot
be justified. Although some experts recommend insertion
of a filter in patients with frec-floating thrombi, the neces-
sity for this measure (above and beyond anticoagulant
therapy) has never bccn demonstrated.
I agree with Rosendaal and colleagues that routine an-
ticoagulant therapy is not indicated in asymptomatic pa-
tients with thrombophilia,2 but the data are retrospective,
and a small but clinically important increase in mortality
in these patients cannot bc ruled out. Furthermore, al-
though mortality is the most important complication of
venous thromboembolism, there is substantial associated
morbidity (the post-thrombotic syndrome and chronic
thromboembolic pulmonary hypertension), which may be
rcduccd by long-term anticoagulant therapy.
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A Pitfall in Assessing Gastric Lymphoma after
Bradication of Helicobacter pylori
To the Editor: Various studies have suggested an impor-
tant role for Helicobacter pylori infection in the pathogen-
esis of low-grade gastric mucosa-associated lymphoid tis-
sue (MALT) lymphoma. These lymphomas may regress
after eradication of H. pylori by antibiotics.1"3 We describe
a patient in whom regression of a large infiltrating low-
grade gastric lymphoma after antibiotic treatment was
docpmented pathologically, although the macroscopic ap-
pearance of the tumor had not changed.
A 39-year-old woman with a short history of epigastric
pain was admitted to our clinic in September 1993. En-
doscopy revealed a 3-cm-by-2-cm polypoid lesion in the
gastric fundus (Fig. 1A). Biopsy specimens showed H. py-
/»«-associated gastritis and features of a low-grade B-cell
MALT lymphoma. Staging procedures, including endo-
scopic ultrasonography, demonstrated that the lymphoma
was confined to the gastric wall (stage EI2 according to
the modified Musshoff staging System). After a two-week
course of omeprazolc (20 mg twice daily) and amoxicillin
(750 mg three times daily), eradication of H. pylori was
documentcd histologically and by means of a rapid urease
test of biopsy specimens from the gastric antrum and cor-
pus. Careful evaluation of repeated biopsies gave no evi-
dence of persisting lymphoma, but the macroscopic ap-
pearance of the fumor was unchanged. Five months later
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